These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 30496442)

  • 1. Mutant p53 in colon cancer.
    Nakayama M; Oshima M
    J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
    Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
    Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
    Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
    Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Mutation of
    Sakai E; Nakayama M; Oshima H; Kouyama Y; Niida A; Fujii S; Ochiai A; Nakayama KI; Mimori K; Suzuki Y; Hong CP; Ock CY; Kim SJ; Oshima M
    Cancer Res; 2018 Mar; 78(5):1334-1346. PubMed ID: 29282223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An N
    Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
    Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
    Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
    Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
    Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
    Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells.
    Shao J; Fujiwara T; Kadowaki Y; Fukazawa T; Waku T; Itoshima T; Yamatsuji T; Nishizaki M; Roth JA; Tanaka N
    Oncogene; 2000 Feb; 19(6):726-36. PubMed ID: 10698490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROCK2/ras
    Masre SF; Rath N; Olson MF; Greenhalgh DA
    Oncogene; 2017 May; 36(18):2529-2542. PubMed ID: 27991921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain-of-Function p53 Mutation Acts as a Genetic Switch for TGFβ Signaling-Induced Epithelial-to-Mesenchymal Transition in Intestinal Tumors.
    Wang D; Nakayama M; Hong CP; Oshima H; Oshima M
    Cancer Res; 2024 Jan; 84(1):56-68. PubMed ID: 37851521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical model of colorectal cancer initiation.
    Paterson C; Clevers H; Bozic I
    Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20681-20688. PubMed ID: 32788368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells.
    Roger L; Jullien L; Gire V; Roux P
    J Cell Sci; 2010 Apr; 123(Pt 8):1295-305. PubMed ID: 20332115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.
    Hinds PW; Finlay CA; Quartin RS; Baker SJ; Fearon ER; Vogelstein B; Levine AJ
    Cell Growth Differ; 1990 Dec; 1(12):571-80. PubMed ID: 2288874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
    Ozawa-Umeta H; Kishimoto A; Imaizumi A; Hashimoto T; Asakura T; Kakeya H; Kanai M
    Cancer Sci; 2020 May; 111(5):1785-1793. PubMed ID: 32163218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
    Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
    PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.